Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

AI Briefing

• – Gilead Sciences to acquire Ouro Medicines for autoimmune disease treatment
• – Acquisition adds clinical-stage BCMAxCD3 T cell engager OM336 to Gilead's portfolio
• – OM336 aims to enable rapid and deep B cell depletion for autoimmune disease treatment